The following articles (labelled with PubMed ID or TBD) are for your review
||The N-Terminal T-T Motif of a Third-Generation HIV-1 Fusion Inhibitor Is Not Required for Binding Affinity and Antiviral Activity.
||Chinese Academy of Medical Sciences& Peking Union Medical College
||Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist.
||GlaxoSmithKline Research and Development
||Structure-directed discovery of an inhibitor of the binding of HIV GP120 to the CD4 receptor
||β-Lactam peptides as potential inhibitors of the HIV gp120-CD4 interaction
||Synthesis of glycolipid analogues that disrupt binding of HIV-1 gp120 to galactosylceramide.
||Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.
||Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design.